With advances in breast cancer therapy, there has been substantial improvement in cancer-specific prognosis for women with breast cancer. As expected, with greater breast cancer survival, risks for competing causes of death have increased in this group of patients, specifically the risk of
Abstract As the clinical applications of immune checkpoint inhibitors (ICIs) expand, our knowledge of the potential adverse effects of these drugs continues to broaden. Emerging…
Abstract Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that have significantly improved the prognosis of various cancers, both in (neo)adjuvant and…
Abstract Avoidance of immune destruction is recognized as one of the hallmarks of cancer development. Although first predicted as a potential antitumor treatment modality more…
Abstract T-cell therapies, such as chimeric antigen receptor (CAR) T-cell, bispecific T-cell engager (BiTE) and tumor-infiltrating lymphocyte (TIL) therapies, fight cancer cells harboring specific …
Abstract Background Trametinib is a MEK1 (mitogen-activated extracellular signal-related kinase kinase 1) inhibitor used in the treatment of BRAF (rapid accelerated fibrosarcoma B-type)–mutated met…
IntroductionAllostatic load (AL) is a score calculated through biomarkers involving the cardiovascular, metabolic, and inflammatory systems that reflects the cumulative effect of stress caused by…
Abstract As the clinical applications of immune checkpoint inhibitors (ICIs) expand, our knowledge of the potential adverse effects of these drugs continues to broaden. Emerging…
